According to a new study published in the journal Nature Medicine, any drug, approved or experimental, can pose a threat to the liver.
The study was carried out by a consortium of scientists from Cincinnati Children’s, Tokyo Medical and Dental University, Takeda Pharmaceutical Co in Japan, and several other research centres in Japan, Europe, and the US.
A corresponding author, Takanori Takebe, MD, an organoid expert at Cincinnati Children’s said in the study: “Our genetic score will potentially benefit people directly as a consumer diagnostic-like application, such as 23andMe and others. People could take the genetic test and know their risk of developing DILI (drug-induced liver injury).”
The research team developed the risk score by re-analysing hundreds of genome-wide association studies (GWAS).
The team found a long list of gene variants that could reveal the likelihood of a poor reaction in the liver to various compounds of the drug.
The researchers believe that this will help doctors and medical health practitioners change doses or formulate a new prescription entirely according to how patients’ livers react to the drug.
Researchers maintained that the gene tests could help exclude people at high risk of liver injury from a clinical trial or high dose of medication as their liver reactions can be more accurately assessed.
Takebe added that more research is needed that could involve a diverse population to confirm the initial findings and to scale up a DILI screening test for potentially widespread use.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.